McMillan David
The Queensland Institute of Medical Research, Bacterial Pathogenesis Laboratory, Brisbane, Australia.
Curr Opin Investig Drugs. 2006 Feb;7(2):186-90.
ID Biomedical, under license from the University of Tennessee, is developing StreptAvax, a potential subunit vaccine against group A streptococcal infection. By January 2005, analysis of data from phase II clinical trials conducted in adults was completed. Pediatric trials are not expected to begin before 2007.
ID生物医学公司在获得田纳西大学许可后，正在研发StreptAvax，这是一种针对A组链球菌感染的潜在亚单位疫苗。到2005年1月，针对成人进行的II期临床试验数据分析已完成。儿科试验预计在2007年之前不会开始。
